JP2006510673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510673A5 JP2006510673A5 JP2004559413A JP2004559413A JP2006510673A5 JP 2006510673 A5 JP2006510673 A5 JP 2006510673A5 JP 2004559413 A JP2004559413 A JP 2004559413A JP 2004559413 A JP2004559413 A JP 2004559413A JP 2006510673 A5 JP2006510673 A5 JP 2006510673A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- alkyl
- indol
- oxo
- perfluoroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- -1 -CH 2 -heteroaryl Chemical group 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 150000002148 esters Chemical group 0.000 claims description 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- TVDZLGHJDRXSPR-UHFFFAOYSA-N 2-[1-(cyclobutylmethyl)-5-prop-2-enoxyindol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(OCC=C)C=C2C(C(=O)C(=O)O)=CN1CC1CCC1 TVDZLGHJDRXSPR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 2
- BHYSBKUSUMQEDF-UHFFFAOYSA-N 1-[4-[(5-ethoxycarbonylfuran-2-yl)methoxy]phenyl]-5-fluoro-2-formylindole-3-carboxylic acid Chemical compound O1C(C(=O)OCC)=CC=C1COC1=CC=C(N2C3=CC=C(F)C=C3C(C(O)=O)=C2C=O)C=C1 BHYSBKUSUMQEDF-UHFFFAOYSA-N 0.000 claims description 2
- MTIRVIPDQBZVPX-UHFFFAOYSA-N 2-(1-benzyl-5-phenylmethoxyindol-3-yl)-2-oxoacetic acid Chemical compound C12=CC=C(OCC=3C=CC=CC=3)C=C2C(C(=O)C(=O)O)=CN1CC1=CC=CC=C1 MTIRVIPDQBZVPX-UHFFFAOYSA-N 0.000 claims description 2
- DRPFVQGQDQAUQP-UHFFFAOYSA-N 2-[1,5-bis[4-(trifluoromethoxy)phenyl]indol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C(C(=O)C(=O)O)=CN1C1=CC=C(OC(F)(F)F)C=C1 DRPFVQGQDQAUQP-UHFFFAOYSA-N 0.000 claims description 2
- CVAKCQKTWWHSDL-UHFFFAOYSA-N 2-[1-[4-[(2,4-dichlorophenyl)methoxy]phenyl]-5-methylindol-3-yl]-2-oxoacetic acid Chemical compound C1=C(C(=O)C(O)=O)C2=CC(C)=CC=C2N1C(C=C1)=CC=C1OCC1=CC=C(Cl)C=C1Cl CVAKCQKTWWHSDL-UHFFFAOYSA-N 0.000 claims description 2
- ZJNNARNIAJBQIG-UHFFFAOYSA-N 2-[1-[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]-5-fluoroindol-3-yl]-2-oxoacetic acid Chemical compound COC1=CC(OC)=CC(COC=2C=CC(=CC=2)N2C3=CC=C(F)C=C3C(C(=O)C(O)=O)=C2)=C1 ZJNNARNIAJBQIG-UHFFFAOYSA-N 0.000 claims description 2
- GNNWWHTUVNXPSE-UHFFFAOYSA-N 2-[1-[4-[(3-chlorophenyl)methoxy]phenyl]-5-methylindol-3-yl]-2-oxoacetic acid Chemical compound C1=C(C(=O)C(O)=O)C2=CC(C)=CC=C2N1C(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 GNNWWHTUVNXPSE-UHFFFAOYSA-N 0.000 claims description 2
- TZHYUUMDKOHMCF-UHFFFAOYSA-N 2-[1-[4-[(4-cyanophenyl)methoxy]phenyl]-5-fluoroindol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(F)C=C2C(C(=O)C(=O)O)=CN1C(C=C1)=CC=C1OCC1=CC=C(C#N)C=C1 TZHYUUMDKOHMCF-UHFFFAOYSA-N 0.000 claims description 2
- ATEZGFIJQUZCGK-UHFFFAOYSA-N 2-[1-[4-[(4-cyanophenyl)methoxy]phenyl]indol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=CC=C2C(C(=O)C(=O)O)=CN1C(C=C1)=CC=C1OCC1=CC=C(C#N)C=C1 ATEZGFIJQUZCGK-UHFFFAOYSA-N 0.000 claims description 2
- FNJSRAMSUGWQOE-UHFFFAOYSA-N 2-[1-[4-[(4-tert-butylphenyl)methoxy]phenyl]-5-methylindol-3-yl]-2-oxoacetic acid Chemical compound C1=C(C(=O)C(O)=O)C2=CC(C)=CC=C2N1C(C=C1)=CC=C1OCC1=CC=C(C(C)(C)C)C=C1 FNJSRAMSUGWQOE-UHFFFAOYSA-N 0.000 claims description 2
- FEGXMJMFVUACQW-UHFFFAOYSA-N 2-[1-benzyl-5-[2-chloro-4-(trifluoromethyl)phenoxy]indol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(OC=3C(=CC(=CC=3)C(F)(F)F)Cl)C=C2C(C(=O)C(=O)O)=CN1CC1=CC=CC=C1 FEGXMJMFVUACQW-UHFFFAOYSA-N 0.000 claims description 2
- ODXJEZZYAFVFOA-UHFFFAOYSA-N 2-[5-[2-(4-fluorophenyl)ethoxy]-1-[(4-fluorophenyl)methyl]indol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(OCCC=3C=CC(F)=CC=3)C=C2C(C(=O)C(=O)O)=CN1CC1=CC=C(F)C=C1 ODXJEZZYAFVFOA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- YQKWTFPVGFGNJW-UHFFFAOYSA-N 5-chloro-1-[3-[(5-ethoxycarbonylfuran-2-yl)methoxy]phenyl]-2-formylindole-3-carboxylic acid Chemical compound O1C(C(=O)OCC)=CC=C1COC1=CC=CC(N2C3=CC=C(Cl)C=C3C(C(O)=O)=C2C=O)=C1 YQKWTFPVGFGNJW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 21
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 4
- 229920001774 Perfluoroether Polymers 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- UYGWFCIWPIVBJA-UHFFFAOYSA-N 2-[1-[4-[(2,6-dichloropyridin-4-yl)methoxy]phenyl]-5-methylindol-3-yl]-2-oxoacetic acid Chemical compound C1=C(C(=O)C(O)=O)C2=CC(C)=CC=C2N1C(C=C1)=CC=C1OCC1=CC(Cl)=NC(Cl)=C1 UYGWFCIWPIVBJA-UHFFFAOYSA-N 0.000 claims 1
- LSJPCRCLJHFBJP-UHFFFAOYSA-N 2-oxo-2-[1-[4-[[4-(thiadiazol-4-yl)phenyl]methoxy]phenyl]indol-3-yl]acetic acid Chemical compound C12=CC=CC=C2C(C(=O)C(=O)O)=CN1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C1=CSN=N1 LSJPCRCLJHFBJP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010003162 Arterial injury Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008132 Cerebral thrombosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000020764 fibrinolysis Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 11
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 11
- 229960000187 tissue plasminogen activator Drugs 0.000 description 11
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 10
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 102000043283 human SERPINE1 Human genes 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 2
- STICGQRKPLURKK-UHFFFAOYSA-N 1,5-bis[4-(trifluoromethoxy)phenyl]indole Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(N(C=C2)C=3C=CC(OC(F)(F)F)=CC=3)C2=C1 STICGQRKPLURKK-UHFFFAOYSA-N 0.000 description 2
- CJJDJQFZVLGJLB-UHFFFAOYSA-N 1-(4-methoxyphenyl)indole Chemical compound C1=CC(OC)=CC=C1N1C2=CC=CC=C2C=C1 CJJDJQFZVLGJLB-UHFFFAOYSA-N 0.000 description 2
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 2
- NCLYASZGRPCNLM-UHFFFAOYSA-N 4-indol-1-ylphenol Chemical compound C1=CC(O)=CC=C1N1C2=CC=CC=C2C=C1 NCLYASZGRPCNLM-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- BTHIGJGJAPYFSJ-UHFFFAOYSA-N 1-(bromomethyl)-3,5-dimethoxybenzene Chemical compound COC1=CC(CBr)=CC(OC)=C1 BTHIGJGJAPYFSJ-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- QZNQSIHCDAGZIA-UHFFFAOYSA-N 1-(bromomethyl)-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(CBr)C=C1 QZNQSIHCDAGZIA-UHFFFAOYSA-N 0.000 description 1
- GYBMJVZOZTVDKS-UHFFFAOYSA-N 1-iodo-2-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC=C1I GYBMJVZOZTVDKS-UHFFFAOYSA-N 0.000 description 1
- RSHBAGGASAJQCH-UHFFFAOYSA-N 1-iodo-3-methoxybenzene Chemical compound COC1=CC=CC(I)=C1 RSHBAGGASAJQCH-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- CTASQNRTEQOJDK-UHFFFAOYSA-N 2-(4-indol-1-ylphenoxy)-2-phenylacetonitrile Chemical compound C1=CC=C(C=C1)C(C#N)OC2=CC=C(C=C2)N3C=CC4=CC=CC=C43 CTASQNRTEQOJDK-UHFFFAOYSA-N 0.000 description 1
- AFMCAWBAQSCVIJ-UHFFFAOYSA-N 2-[5-chloro-1-[3-[(3,5-dimethoxyphenyl)methoxy]phenyl]indol-3-yl]-2-oxoacetic acid Chemical compound COC1=CC(OC)=CC(COC=2C=C(C=CC=2)N2C3=CC=C(Cl)C=C3C(C(=O)C(O)=O)=C2)=C1 AFMCAWBAQSCVIJ-UHFFFAOYSA-N 0.000 description 1
- VYWNKGPTZQDPSH-UHFFFAOYSA-N 2-[5-chloro-1-[3-[(4-cyanophenyl)methoxy]phenyl]indol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(Cl)C=C2C(C(=O)C(=O)O)=CN1C(C=1)=CC=CC=1OCC1=CC=C(C#N)C=C1 VYWNKGPTZQDPSH-UHFFFAOYSA-N 0.000 description 1
- MBYOXHQNYRONJG-UHFFFAOYSA-N 2-[5-chloro-1-[3-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methoxy]phenyl]indol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(Cl)C=C2C(C(=O)C(=O)O)=CN1C(C=1)=CC=CC=1OCC1=C(F)C(F)=C(C(F)(F)F)C(F)=C1F MBYOXHQNYRONJG-UHFFFAOYSA-N 0.000 description 1
- ZTFBRYAJTSQNQE-UHFFFAOYSA-N 2-[5-chloro-1-[3-[[4-(thiadiazol-4-yl)phenyl]methoxy]phenyl]indol-3-yl]-2-oxoacetic acid Chemical compound C12=CC=C(Cl)C=C2C(C(=O)C(=O)O)=CN1C(C=1)=CC=CC=1OCC(C=C1)=CC=C1C1=CSN=N1 ZTFBRYAJTSQNQE-UHFFFAOYSA-N 0.000 description 1
- XDKGMGJZRFOZRV-UHFFFAOYSA-N 4-(bromomethyl)-2,6-dichloropyridine Chemical compound ClC1=CC(CBr)=CC(Cl)=N1 XDKGMGJZRFOZRV-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- PCQVWCHZMARESC-UHFFFAOYSA-N 5-[4-(trifluoromethoxy)phenyl]-1h-indole Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(NC=C2)C2=C1 PCQVWCHZMARESC-UHFFFAOYSA-N 0.000 description 1
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 1
- YPKBCLZFIYBSHK-UHFFFAOYSA-N 5-methylindole Chemical compound CC1=CC=C2NC=CC2=C1 YPKBCLZFIYBSHK-UHFFFAOYSA-N 0.000 description 1
- CJOAAJIGYICLNT-UHFFFAOYSA-N 5-prop-2-enoxy-1h-indole Chemical compound C=CCOC1=CC=C2NC=CC2=C1 CJOAAJIGYICLNT-UHFFFAOYSA-N 0.000 description 1
- ONYNOPPOVKYGRS-UHFFFAOYSA-N 6-methylindole Natural products CC1=CC=C2C=CNC2=C1 ONYNOPPOVKYGRS-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- YRHVTNFFGLSGHS-RFNIADBLSA-N acetic acid;(2s)-5-(diaminomethylideneamino)-2-[[2-[[(2r)-3-(4-hydroxycyclohexyl)-2-(methanesulfonamido)propanoyl]amino]acetyl]amino]-n-(4-nitrophenyl)pentanamide Chemical compound CC(O)=O.C([C@@H](NS(=O)(=O)C)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1CCC(O)CC1 YRHVTNFFGLSGHS-RFNIADBLSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- WPOPOPFNZYPKAV-UHFFFAOYSA-N cyclobutylmethanol Chemical compound OCC1CCC1 WPOPOPFNZYPKAV-UHFFFAOYSA-N 0.000 description 1
- LFPLOYLKHHNDLO-UHFFFAOYSA-N disodium;trimethylsilylazanide Chemical compound [Na+].[Na+].C[Si](C)(C)[NH-].C[Si](C)(C)[NH-] LFPLOYLKHHNDLO-UHFFFAOYSA-N 0.000 description 1
- FQTGVFWUFSBTIG-UHFFFAOYSA-N ethyl 2-[1,5-bis[4-(trifluoromethoxy)phenyl]indol-3-yl]-2-oxoacetate Chemical compound C12=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C(C(=O)C(=O)OCC)=CN1C1=CC=C(OC(F)(F)F)C=C1 FQTGVFWUFSBTIG-UHFFFAOYSA-N 0.000 description 1
- JBACYJRMCXLIQU-UHFFFAOYSA-N ethyl 5-(chloromethyl)furan-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(CCl)O1 JBACYJRMCXLIQU-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43232902P | 2002-12-10 | 2002-12-10 | |
| PCT/US2003/038934 WO2004052854A2 (en) | 2002-12-10 | 2003-12-09 | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510673A JP2006510673A (ja) | 2006-03-30 |
| JP2006510673A5 true JP2006510673A5 (enExample) | 2006-11-16 |
Family
ID=32507901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559413A Pending JP2006510673A (ja) | 2002-12-10 | 2003-12-09 | プラスミノゲンアクティベータインヒビター１（ｐａｉ−１）のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換１ｈ−インドール−３−イルグリオキシル酸誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7259182B2 (enExample) |
| EP (1) | EP1569901B1 (enExample) |
| JP (1) | JP2006510673A (enExample) |
| CN (1) | CN1723198A (enExample) |
| AT (1) | ATE411288T1 (enExample) |
| AU (1) | AU2003296324A1 (enExample) |
| BR (1) | BR0316585A (enExample) |
| CA (1) | CA2509191A1 (enExample) |
| DE (1) | DE60324183D1 (enExample) |
| DK (1) | DK1569901T3 (enExample) |
| ES (1) | ES2314289T3 (enExample) |
| MX (1) | MXPA05006283A (enExample) |
| WO (1) | WO2004052854A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2290318T3 (es) | 2001-06-20 | 2008-02-16 | Wyeth | Derivados sustituidos de acido indolico como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
| TWI224101B (en) * | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| AU2003296324A1 (en) | 2002-12-10 | 2004-06-30 | Wyeth | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| JP2006514640A (ja) * | 2002-12-10 | 2006-05-11 | ワイス | プラスミノゲンアクティベータインヒビターのインヒビターとしての置換３−アルキル及び３−アリールアルキル１ｈ−イル酢酸誘導体 |
| MXPA05006287A (es) | 2002-12-10 | 2005-09-08 | Wyeth Corp | Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1). |
| WO2004052855A2 (en) * | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| US7411083B2 (en) * | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
| US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| US7446201B2 (en) * | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US7442805B2 (en) * | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7534894B2 (en) * | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| US7351726B2 (en) * | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7186749B2 (en) * | 2004-08-23 | 2007-03-06 | Wyeth | Pyrrolo-naphthyl acids and methods for using them |
| BRPI0514572A (pt) | 2004-08-23 | 2008-06-17 | Wyeth Corp | ácidos de tiazolo-naftila |
| KR20070055563A (ko) | 2004-08-23 | 2007-05-30 | 와이어쓰 | 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산 |
| US7683091B2 (en) | 2005-08-17 | 2010-03-23 | Wyeth | Substituted indoles and methods of their use |
| CN101384256A (zh) * | 2006-02-27 | 2009-03-11 | 惠氏公司 | 用于治疗肌肉病状的pai-1抑制剂 |
| PA8768201A1 (es) * | 2007-02-05 | 2009-01-23 | Wyeth Corp | Composiciones farmacéuticas que contienen derivados de ácido indol sustituidos como inhibidores del inhibidor del activador de plasminógeno 1 (pai-1) |
| WO2008097953A2 (en) * | 2007-02-05 | 2008-08-14 | Wyeth | Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| RU2492164C2 (ru) * | 2008-04-16 | 2013-09-10 | Каро Био Аб | Новые лиганды эстрогеновых рецепторов |
| GB0812192D0 (en) * | 2008-07-03 | 2008-08-13 | Lectus Therapeutics Ltd | Calcium ion channel modulators & uses thereof |
| EP2361093A2 (en) | 2008-11-26 | 2011-08-31 | Five Prime Therapeutics, Inc. | Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2 |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| CN102335168B (zh) * | 2011-10-25 | 2014-04-02 | 合肥博太医药生物技术发展有限公司 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用 |
| CN102335169B (zh) * | 2011-10-25 | 2014-03-19 | 合肥博太医药生物技术发展有限公司 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗老年痴呆药物中的应用 |
| CN102429901B (zh) * | 2011-11-03 | 2013-11-06 | 合肥博太医药生物技术发展有限公司 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治肾纤维化药物中的应用 |
| CN114456143B (zh) * | 2022-02-23 | 2023-08-15 | 北京丰帆生物医药科技有限公司 | 一种uPA的抑制剂及其制备方法和应用 |
| WO2025141118A1 (en) * | 2023-12-27 | 2025-07-03 | Institut National de la Santé et de la Recherche Médicale | Arylalkyloxyindole compounds and derivatives and their use |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3026325A (en) * | 1959-01-26 | 1962-03-20 | Upjohn Co | 5-hydroxy-alpha-alkyltryptophans |
| NL125657C (enExample) * | 1963-11-26 | |||
| US3476770A (en) * | 1967-04-14 | 1969-11-04 | Parke Davis & Co | 2-methyl-7-phenylindole-3-acetic acid compounds |
| GB1321433A (en) | 1968-01-11 | 1973-06-27 | Roussel Uclaf | 1,2,3,6-tetrasubstituted indoles |
| US3557142A (en) * | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| FR2244499A1 (en) | 1973-06-07 | 1975-04-18 | Delalande Sa | Indol-3-ylformaldoxime carbamates - for treating anxiety epilepsy, cardiac arrhythmias, asthma, intestinal spasm, peptic ulcer, cardiac insufficiency |
| DE3147276A1 (de) | 1981-11-28 | 1983-06-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole |
| FR2525474A1 (fr) * | 1982-04-26 | 1983-10-28 | Roussel Uclaf | Nouvelle forme pharmaceutique orale de clometacine |
| DE3531658A1 (de) * | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel |
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| PH30133A (en) | 1989-09-07 | 1997-01-21 | Abbott Lab | Indole-, benzofuran-, and benzothiophene-containing lipoxygenase inhibiting compounds |
| US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| DE4035961A1 (de) * | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5151435A (en) | 1991-04-08 | 1992-09-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating an indole or dihydroindole |
| IL101785A0 (en) | 1991-05-10 | 1992-12-30 | Fujisawa Pharmaceutical Co | Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| GB9123396D0 (en) * | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
| US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| DE4242675A1 (de) | 1992-12-17 | 1994-06-23 | Basf Ag | Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung |
| ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| IL109568A0 (en) | 1993-05-19 | 1994-08-26 | Fujisawa Pharmaceutical Co | Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| DE4338770A1 (de) | 1993-11-12 | 1995-05-18 | Matthias Dr Lehr | Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5482960A (en) * | 1994-11-14 | 1996-01-09 | Warner-Lambert Company | Nonpeptide endothelin antagonists |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| IL117208A0 (en) | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
| US6069156A (en) | 1995-04-10 | 2000-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives as cGMP-PDE inhibitors |
| US5728724A (en) | 1995-08-17 | 1998-03-17 | Eli Lilly And Company | Benzothiophene compounds |
| BR9606619A (pt) | 1995-09-01 | 1997-12-23 | Lilly Co Eli | Antagonistas do receptor de neuropeptídeo y indolil |
| DE19543639A1 (de) | 1995-11-23 | 1997-05-28 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
| GB9609641D0 (en) | 1996-05-09 | 1996-07-10 | Pfizer Ltd | Compounds useful in therapy |
| CA2258728C (en) * | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| CA2207083A1 (en) * | 1996-07-15 | 1998-01-15 | Brian William Grinnell | Benzothiophene compounds, and uses and formulations thereof |
| US5859044A (en) * | 1996-07-31 | 1999-01-12 | Pfizer Inc. | β-adrenergic agonists |
| AU717430B2 (en) | 1996-08-26 | 2000-03-23 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| DE19753522A1 (de) | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
| PL343007A1 (en) * | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
| EA200000873A1 (ru) | 1998-02-25 | 2001-04-23 | Дженетикс Инститьют, Инк. | Ингибиторы фосфолипазы a |
| SK12742000A3 (sk) | 1998-02-25 | 2001-05-10 | Genetics Institute, Inc. | Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie |
| SE9800836D0 (sv) * | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
| IL138711A0 (en) | 1998-03-31 | 2001-10-31 | Inst Pharmaceutical Discovery | Substituted indolealkanoic acids |
| FR2777886B1 (fr) | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| HRP20000767A2 (en) | 1998-05-12 | 2001-10-31 | American Home Prod | Benzothiophenes, benzofurans and indoles useful in the treatment of insulin resistance and hyperglycemia |
| EP1077965A1 (en) | 1998-05-12 | 2001-02-28 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| US6232322B1 (en) * | 1998-05-12 | 2001-05-15 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| US6110963A (en) * | 1998-05-12 | 2000-08-29 | American Home Products Corporation | Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| US6251936B1 (en) * | 1998-05-12 | 2001-06-26 | American Home Products Corporation | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia |
| US6166069A (en) * | 1998-05-12 | 2000-12-26 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| AU2097100A (en) * | 1998-12-16 | 2000-07-03 | Boehringer Ingelheim Pharma Kg | Substituted aryl and heteroaryl derivatives, their production and their use as medicines |
| GB9827882D0 (en) | 1998-12-17 | 1999-02-10 | Smithkline Beecham Plc | Novel compounds |
| WO2000044743A1 (en) | 1999-01-28 | 2000-08-03 | Nippon Shinyaku Co., Ltd. | Amide derivatives and drug compositions |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| EE200100558A (et) | 1999-04-28 | 2002-12-16 | Aventis Pharma Deutschland Gmbh | Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine |
| EE200100556A (et) | 1999-04-28 | 2003-02-17 | Aventis Pharma Deutschland Gmbh | Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks |
| GB9919413D0 (en) * | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| FR2799756B1 (fr) | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE19963178A1 (de) * | 1999-12-27 | 2001-07-05 | Gruenenthal Gmbh | Substituierte Indol-Mannichbasen |
| PL366068A1 (en) | 2000-10-10 | 2005-01-24 | Smithkline Beecham Corporation | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| FR2825706B1 (fr) * | 2001-06-06 | 2003-12-12 | Pf Medicament | Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase |
| TWI240723B (en) * | 2001-06-20 | 2005-10-01 | Wyeth Corp | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| US7291639B2 (en) * | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| ES2290318T3 (es) * | 2001-06-20 | 2008-02-16 | Wyeth | Derivados sustituidos de acido indolico como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
| TWI224101B (en) * | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| KR100810468B1 (ko) * | 2001-10-10 | 2008-03-07 | 씨제이제일제당 (주) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체 |
| AU2003209130B2 (en) | 2002-02-12 | 2008-06-05 | Wisconsin Alumni Research Foundation | Synthesis of indole thiazole compounds as ligands for the AH receptor |
| WO2003087087A2 (en) | 2002-04-09 | 2003-10-23 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| WO2004052855A2 (en) * | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| AU2003296324A1 (en) * | 2002-12-10 | 2004-06-30 | Wyeth | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| JP2006514640A (ja) * | 2002-12-10 | 2006-05-11 | ワイス | プラスミノゲンアクティベータインヒビターのインヒビターとしての置換３−アルキル及び３−アリールアルキル１ｈ−イル酢酸誘導体 |
| MXPA05006287A (es) * | 2002-12-10 | 2005-09-08 | Wyeth Corp | Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1). |
| UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| US7351726B2 (en) * | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7420083B2 (en) * | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
| US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US7446201B2 (en) * | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| US7442805B2 (en) * | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US20050215626A1 (en) * | 2003-09-25 | 2005-09-29 | Wyeth | Substituted benzofuran oximes |
| US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| KR20060096038A (ko) | 2003-10-16 | 2006-09-05 | 화이자 프로덕츠 인크. | 3-아자비시클로〔3.1.0〕헥산 유도체의 제조법 |
-
2003
- 2003-12-09 AU AU2003296324A patent/AU2003296324A1/en not_active Withdrawn
- 2003-12-09 DE DE60324183T patent/DE60324183D1/de not_active Expired - Lifetime
- 2003-12-09 US US10/731,308 patent/US7259182B2/en not_active Expired - Fee Related
- 2003-12-09 DK DK03812847T patent/DK1569901T3/da active
- 2003-12-09 JP JP2004559413A patent/JP2006510673A/ja active Pending
- 2003-12-09 MX MXPA05006283A patent/MXPA05006283A/es active IP Right Grant
- 2003-12-09 ES ES03812847T patent/ES2314289T3/es not_active Expired - Lifetime
- 2003-12-09 CN CNA2003801054475A patent/CN1723198A/zh not_active Withdrawn
- 2003-12-09 AT AT03812847T patent/ATE411288T1/de not_active IP Right Cessation
- 2003-12-09 WO PCT/US2003/038934 patent/WO2004052854A2/en not_active Ceased
- 2003-12-09 EP EP03812847A patent/EP1569901B1/en not_active Expired - Lifetime
- 2003-12-09 CA CA002509191A patent/CA2509191A1/en not_active Abandoned
- 2003-12-09 BR BR0316585-0A patent/BR0316585A/pt not_active IP Right Cessation
-
2007
- 2007-07-11 US US11/827,579 patent/US7674818B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510673A5 (enExample) | ||
| US7674818B2 (en) | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | |
| EP1569899B1 (en) | Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| US6800654B2 (en) | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | |
| US7074817B2 (en) | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | |
| EP1569900B1 (en) | Substituted 3-carbonyl-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| EP1569902A1 (en) | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| JP2010513224A (ja) | Ｃｒｔｈ２拮抗剤および抗アレルギー剤として有用な多環酸化合物 | |
| AU2002316533A1 (en) | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | |
| EP1844771A2 (en) | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | |
| HK1109588A (en) | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |